Matteo Augello
Overview
Explore the profile of Matteo Augello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
385
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lundgren L, Albertini L, De Bona A, Tincati C, Augello M, Marchetti G
JAC Antimicrob Resist
. 2025 Mar;
7(2):dlaf032.
PMID: 40046068
Background: The POET trial, along with other studies, indicated that switching from IV to partial oral treatment (POT) in selected infective endocarditis (IE) cases is as effective as the traditional...
2.
Augello M, Bono V, Rovito R, Santoro A, Tincati C, Marchetti G
AIDS
. 2024 Oct;
38(14):1987-1990.
PMID: 39474654
In this prospective longitudinal study, we evaluated the durability of humoral responses to SARS-CoV-2 mRNA booster vaccination in 93 people with HIV, exploring the possible role of T-cell dysfunction and...
3.
Augello M, Wagenhauser I, Krone M, Dauby N, Ferrara P, Sabbatucci M, et al.
Vaccine
. 2024 Aug;
42(25):126184.
PMID: 39097440
Anti-SARS-CoV-2 vaccination has saved millions of lives in the past few years. To maintain a high level of protection, particularly in at-risk populations, booster doses are recommended to counter the...
4.
Bai F, Beringheli T, Vitaletti V, Santoro A, Mola F, Copes A, et al.
Infect Dis Ther
. 2024 Jun;
13(7):1589-1605.
PMID: 38829439
Introduction: We compared the effectiveness and virological clearance (VC) at day 7 (T7) post-treatment with molnupiravir, nirmatrelvir/ritonavir, and remdesivir in SARS-CoV-2-infected patients at high risk (HR) for clinical progression. Methods:...
5.
Montesi G, Augello M, Polvere J, Marchetti G, Medaglini D, Ciabattini A
J Transl Med
. 2024 May;
22(1):432.
PMID: 38715088
Background: SARS-CoV-2 mRNA vaccines are highly immunogenic in people living with HIV (PLWH) on effective antiretroviral therapy (ART). However, whether viro-immunologic parameters or other factors affect immune responses to vaccination...
6.
Augello M, Bono V, Rovito R, Tincati C, Bianchi S, Taramasso L, et al.
iScience
. 2024 Jan;
27(1):108673.
PMID: 38188525
Severe COVID-19 outcomes have been reported in people living with HIV (PLWH), yet the underlying pathogenetic factors are largely unknown. We therefore aimed to assess SARS-CoV-2 RNAemia and plasma cytokines...
7.
Tincati C, Bono V, Cannizzo E, Tosi D, Savi F, Falcinella C, et al.
AIDS
. 2023 Nov;
38(5):623-632.
PMID: 38016163
Introduction: Impairment of the gastrointestinal barrier leads to microbial translocation and peripheral immune activation, which are linked to disease progression. Data in the setting of primary HIV/SIV infection suggest that...
8.
Vergori A, Tavelli A, Matusali G, Azzini A, Augello M, Mazzotta V, et al.
Vaccines (Basel)
. 2023 Nov;
11(11).
PMID: 38005996
Background: Our aim was to estimate the rates of not achieving a robust/above-average humoral response to the COVID-19 mRNA vaccine in people living with HIV (PLWH) who received ≥2 doses...
9.
Giacomelli A, Gagliardini R, Tavelli A, De Benedittis S, Mazzotta V, Rizzardini G, et al.
Int J Infect Dis
. 2023 Sep;
136:127-135.
PMID: 37741311
Objectives: We aimed to study whether people living with HIV (PLWH) are at higher risk of in-hospital COVID-19 mortality compared to the general population (GenPop). Methods: This was a retrospective...
10.
Augello M, Bono V, Rovito R, Tincati C, Monforte A, Marchetti G
AIDS
. 2023 May;
37(10):1503-1517.
PMID: 37199415
Objective: Immune responses to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccines in people with HIV (PWH) with a history of late presentation (LP) and their durability have not...